SAR443122

DB16492InvestigationalSmall molecule

SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally,... Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus.

Mechanism: SAR443122 inhibits receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It is currently being investigated against inflammatory diseases such as rheumatoid arthritis and psoriasis, and against hyperinflammatory states in patients with severe COVID-19.
Curator reviewed
Formula / weight: C₁₉H₁₈N₆O₃ · 378.392 g/mol (avg)
Also known as: 1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)- · 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE · ECLITASERTIB
Code names: DNL 758 · SAR443122

Resolves to

Compound

UNII975AT1P9J6CAS2125450-76-0ChEMBLCHEMBL4861471

Structure

InChIKeyXUZICJHIIJCKQQ-ZDUSSCGKSA-NSMILESCN1C2=NC=CC=C2OC[C@H](NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C1=O

Targets

Q13546RIPK1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with SAR443122, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account